Navitoclax (ABT-263) | Bcl-2 inhibitor

Chemical Structure : Navitoclax

CAS No.: 923564-51-6

Navitoclax (ABT-263, ABT263)

Catalog No.: PC-42277Not For Human Use, Lab Use Only.

Navitoclax (ABT-263) is a potent, orally bioavailable Bcl-2 family inhibitor with Ki of <1 nM for Bcl-2, Bcl-xL, and Bcl-w.

Packing	Price	Stock
10 mg	$78	In stock
50 mg	$128	In stock
100 mg	$218	In stock
250 mg	$378	In stock
1 g		Get quote

Get Quotation Now

* Please select Quantity before adding items.

or Bulk Inquiry

Bulk size, bulk discount!

E-mail: sales@probechem.com

Tech Support: tech@probechem.com

Biological Activity

Navitoclax (ABT-263) is a potent, orally bioavailable Bcl-2 family inhibitor with Ki of <1 nM for Bcl-2, Bcl-xL, and Bcl-w.
Navitoclax (ABT-263) binds more weakly to Mcl-1 and A1 (Ki>350 nM).
Navitoclax (ABT-263) disrupts Bcl-2/Bcl-xL interactions with pro-death proteins (e.g., Bim), induces apoptosis, shows cellular activity against a panel of human tumor cell lines (EC50<1 uM).
Navitoclax (ABT-263) induces complete tumor regressions in xenograft models of NSCLA and ALL.

Physicochemical Properties

M.Wt	974.6127
Formula	C47H55ClF3N5O6S3
Appearance	Solid
CAS No.
Storage	Solide Powder -20 °C 12 Months; 4°C 6 Months	In Solvent -80 °C 6 Months; -20°C 6 Months
Shipping
Solubility	10 mM in DMSO
Chemical Name/SMILES	Benzamide, 4-[4-[[2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[4-[[(1R)-3-(4-morpholinyl)-1-[(phenylthio)methyl]propyl]amino]-3-[(trifluoromethyl)sulfonyl]phenyl]sulfonyl]-

References

1. Tse C, et al. Cancer Res. 2008 May 1;68(9):3421-8.

2. Shoemaker AR, et al. Clin Cancer Res. 2008 Jun 1;14(11):3268-77.

3. Ackler S, et al. Mol Cancer Ther. 2008 Oct;7(10):3265-74.

4. Shah OJ, et al. Proc Natl Acad Sci U S A. 2010 Jul 13;107(28):12634-9.

Navitoclax (ABT-263, ABT263)

Biological Activity

Physicochemical Properties

References

Bulk Inquiry

* Indicates a Required FieldYour information is safe with us.

Get Quote

* Indicates a Required FieldYour information is safe with us.